Litigation Details for Cephalon Inc. v. Actavis Group (D. Del. 2009)

Cephalon Inc. v. Actavis Group (D. Del. 2009)

Docket		Date Filed	2009-12-08
Court	District Court, D. Delaware	Date Terminated	2011-03-22
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Parties	ACTAVIS PHARMA MANUFACTURING PVT LTD.
Patents	7,132,570; RE37,516
Attorneys	Mary W. Bourke
Firms	Womble Carlyle Sandridge & Rice, LLP
Link to Docket	External link to docket

Details for Cephalon Inc. v. Actavis Group (D. Del. 2009)

Date Filed	Document No.	Description	Snippet	Link To Document
2009-12-08				External link to document

Cephalon Inc. v. Actavis Group, 1:09-cv-00940: Litigation Summary and Patent Analysis

Last updated: August 27, 2026

Cephalon Inc. v. Actavis Group, Civil Action No. 1:09-cv-00940, was a District of Delaware Hatch-Waxman case involving Actavis’ proposed generic version of Provigil, Cephalon’s modafinil product. Cephalon filed the action after receiving an abbreviated new drug application, or ANDA, notification containing Paragraph IV certifications against Cephalon’s Provigil patents. The case was part of a broader Cephalon enforcement campaign against generic modafinil applicants.

The litigation ended through a settlement rather than a reported trial judgment on infringement or validity. The settlement formed part of the broader Provigil generic-entry arrangements later examined by the Federal Trade Commission. [1][2]

What drug and product were at issue in Cephalon v. Actavis?

The product was Provigil, an immediate-release tablet containing modafinil.

Product	Active ingredient	Dosage forms	Brand company	Regulatory pathway
Provigil	Modafinil	100 mg and 200 mg tablets	Cephalon Inc.	New Drug Application
Proposed Actavis product	Modafinil	Generic tablets corresponding to Provigil	Actavis Group and affiliated entities	ANDA

Modafinil was approved by the FDA for narcolepsy, obstructive sleep apnea/hypopnea syndrome, and shift-work sleep disorder. The litigation concerned the patent barriers to generic approval and commercial launch, rather than the clinical approval standard for modafinil. [3]

When was Cephalon v. Actavis filed, and what court handled it?

The case was filed in the U.S. District Court for the District of Delaware under docket number 1:09-cv-00940. Cephalon initiated the case after Actavis submitted an ANDA with Paragraph IV certifications asserting that relevant Cephalon patents were invalid, unenforceable, or not infringed.

Under the Hatch-Waxman Act, Cephalon’s patent-infringement complaint triggered an automatic 30-month stay of FDA approval of the Actavis ANDA, subject to earlier termination by court decision or settlement. The stay gave Cephalon time to litigate the listed patents before generic approval could proceed. [4]

Who were the parties?

The principal parties were:

• Cephalon Inc., the Provigil NDA holder and patent owner or exclusive licensee for relevant rights.
• Actavis Group and related Actavis entities, the generic-drug applicant.
• In the broader Provigil litigation, other defendants included Teva, Mylan, Ranbaxy, Sandoz and Apotex-related entities.

Cephalon’s patent strategy involved coordinated litigation against multiple ANDA filers. The cases raised overlapping validity, infringement and settlement issues.

What patents protected Provigil against Actavis?

The Actavis case involved Cephalon’s listed Provigil patent estate, including patents directed to modafinil compositions and formulation characteristics. Public records from the related Provigil litigation identify the following patents as central to the generic-entry dispute:

Patent	General subject matter	Relevance to generic entry
U.S. Patent No. 5,618,845	Modafinil pharmaceutical compositions and use	Earlier composition and product protection
U.S. Patent No. 6,894,051	Modafinil pharmaceutical formulations	Formulation protection
U.S. Patent No. 7,297,346	Modafinil particle-size and composition limitations	Later-expiring formulation protection
U.S. Patent No. 7,348,363	Modafinil composition and formulation claims	Additional formulation barrier

The precise patent claims asserted against Actavis must be distinguished from the complete Orange Book listing. A patent may be listed for a product without every claim being asserted in a particular case. The key commercial issue was whether Actavis’ ANDA product would infringe the later-expiring formulation patents, particularly the patents directed to particle characteristics and composition design. [1][5]

What were the main legal issues in the Paragraph IV litigation?

The case presented the standard ANDA litigation issues:

1. Whether Actavis’ proposed modafinil product would infringe the asserted claims under the statutory ANDA infringement framework.
2. Whether the asserted patents were invalid for obviousness, anticipation, indefiniteness or lack of written description.
3. Whether any patent claims were unenforceable because of inequitable conduct.
4. Whether Actavis’ proposed product could launch before expiry of the relevant patents.
5. Whether the parties could resolve the dispute through a settlement allowing an agreed future entry date.

The formulation patents were commercially important because an invalidity or noninfringement ruling could have opened the market to Actavis before the listed patent expiry dates. Cephalon, in contrast, sought to preserve Provigil sales by maintaining the enforceability of its later-expiring patent claims.

Did Actavis win or lose the patent case?

Neither side obtained a reported merits victory in the docketed Actavis case. The litigation was resolved by settlement.

The settlement meant that:

• Actavis did not proceed to an immediate at-risk launch based on a final invalidity or noninfringement judgment.
• Cephalon avoided the risk of an adverse ruling that could have eliminated its formulation-patent barriers.
• The commercial launch date was controlled by the settlement terms rather than by a final trial judgment.
• The financial and other terms of the individual Cephalon-Actavis agreement were not publicly disclosed in full.

The absence of a merits judgment limits the precedential value of the case. It does not establish that the asserted patents were valid, infringed or enforceable against Actavis.

What was the settlement and when could Actavis enter?

Cephalon entered settlements with several generic manufacturers, including Actavis, in the period before authorized or licensed generic competition reached the market. The FTC later alleged that Cephalon’s agreements delayed generic competition for Provigil and included payments or other valuable consideration to generic companies. [2]

The public record does not provide a complete, stand-alone set of economic terms for the Actavis agreement in the 09-940 docket. The commercial structure must be analyzed together with the broader Provigil settlement program and the later authorized-generic arrangements.

The FTC’s enforcement action alleged that Cephalon paid four generic companies, including Actavis, to delay entry. Cephalon settled the FTC matter in 2015 without admitting liability, agreeing to pay $1.2 billion and to permit generic competition under specified conditions. [2]

What litigation affected the Provigil patent estate?

The Actavis case was one of several related Provigil cases. The most significant appellate decision involved Cephalon’s litigation against generic defendants over U.S. Patent No. 7,348,363. In Cephalon, Inc. v. Watson Pharmaceuticals, Inc., the Federal Circuit addressed the validity and enforceability of claims covering modafinil formulations and affirmed the district court’s decision in material respects. [1]

The broader litigation record included:

Litigation issue	Commercial effect
Paragraph IV certifications	Created the basis for patent litigation before FDA approval
30-month stay	Delayed potential generic approval
Formulation-patent validity	Determined whether later patent protection could block launch
Settlement agreements	Replaced trial outcomes with negotiated entry dates
Authorized generic arrangements	Affected the economic value of delayed independent generic entry
FTC enforcement	Created antitrust exposure for reverse-payment settlement structures

The appellate decisions in related cases provide more substantive guidance than the Actavis docket itself because the Actavis matter did not produce a final reported trial judgment.

What was the Orange Book status of Provigil?

Provigil’s Orange Book strategy relied on multiple listed patents with different expiration profiles. Earlier patents covered the original product and compositions, while later patents were directed toward formulation and particle-size limitations.

The relevant commercial chronology was:

Period	Event
1990s	Original modafinil patents issued
2000s	Additional Provigil formulation patents issued and listed
2009	Cephalon filed the Actavis litigation after the Paragraph IV notice
2011-era	Cephalon entered generic settlements, including the Actavis arrangement
2012	Generic modafinil competition began under negotiated commercial arrangements
2015	Cephalon resolved the FTC antitrust case through a $1.2 billion settlement

Patent expiry did not automatically result in unrestricted generic competition because settlement agreements, authorized-generic arrangements and other commercial terms affected the timing and source of market entry.

How strong was Cephalon’s patent estate?

Cephalon’s estate had moderate-to-strong short-term blocking power but weaker long-term durability.

Strengths

• Multiple listed patents created overlapping litigation barriers.
• Later formulation patents extended protection beyond the earliest composition patents.
• Particle-size and formulation claims created technical distinctions from the original modafinil disclosure.
• The 30-month stay increased the value of settlement leverage.
• Coordinated enforcement against several ANDA filers reduced the risk of an isolated early launch.

Weaknesses

• Formulation patents were vulnerable to obviousness challenges.
• Generic applicants could design products around narrow particle-size or composition limitations.
• Multiple Paragraph IV challenges increased the probability of invalidity or noninfringement findings.
• Settlement payments created substantial antitrust risk.
• The value of the estate declined sharply once authorized and independent generic products entered.

The later patents were commercially important but technically narrower than broad compound patents. Their strength depended on claim construction, the prior-art record, and whether the generic product met the claimed particle-size and formulation limitations.

What generic launch risks existed for Actavis?

Actavis faced four principal launch risks:

1. Injunction risk. Cephalon could seek to prevent commercial launch until patent expiry or a favorable judgment.
2. Damages risk. An at-risk launch could expose Actavis to substantial damages if the patents were later upheld and found infringed.
3. Regulatory delay. The litigation triggered the Hatch-Waxman stay, preventing immediate FDA approval.
4. Settlement restrictions. The agreement could limit the launch date, product source, or commercial terms.

Cephalon faced corresponding risks. A loss on a key formulation patent could have accelerated generic competition and reduced Provigil revenue before the company completed its transition to other products.

Did biosimilar law affect this case?

No. Provigil was a small-molecule drug, and Actavis pursued an ANDA under the Hatch-Waxman framework. The Biologics Price Competition and Innovation Act, biosimilar exclusivity rules and biologic patent dance procedures did not apply.

The relevant competitive threat was generic modafinil, not a biosimilar.

What is the current litigation status?

The Actavis case is closed. It did not result in a current injunction, pending trial or active patent dispute. The settlement resolved the direct litigation, while the broader legal significance of the Provigil settlements was addressed through later antitrust proceedings and appellate decisions involving related defendants.

Key Takeaways

• Cephalon v. Actavis, 1:09-cv-00940, was a District of Delaware ANDA case concerning generic modafinil and Provigil.
• Cephalon asserted its Provigil patent estate, including formulation and particle-size patents.
• The case ended in settlement, not a reported merits judgment.
• The settlement controlled Actavis’ commercial entry and avoided immediate at-risk competition.
• The broader settlement program became the subject of FTC antitrust enforcement.
• Related litigation established more substantive precedent on Provigil patent validity than the Actavis docket itself.
• The estate’s commercial strength came from layered formulation protection, but narrow formulation claims remained vulnerable to design-around and obviousness attacks.
• Biosimilar law was irrelevant because modafinil is a small-molecule drug regulated through the ANDA pathway.

FAQs About Cephalon v. Actavis, 1:09-cv-00940

What was Actavis’ Paragraph IV position for generic modafinil?

Actavis challenged the relevant Provigil patents by asserting that they were invalid, unenforceable or would not be infringed by its ANDA product.

Was U.S. Patent No. 7,297,346 the only patent in the case?

No. The Provigil litigation involved multiple listed patents and related cases. The asserted-patent set must be distinguished from Cephalon’s complete Orange Book listing.

Did Actavis launch generic Provigil before patent expiry?

Actavis’ market entry was governed by settlement arrangements rather than an adverse final judgment against Cephalon.

Did the FTC invalidate Cephalon’s Provigil patents?

No. The FTC proceedings addressed the competitive and antitrust consequences of the settlement agreements. They did not invalidate the patents.

What company acquired Cephalon?

Teva Pharmaceutical Industries acquired Cephalon in 2011. Teva subsequently controlled the Provigil commercial and patent strategy and participated in the later resolution of the FTC matter. [2][6]

References

1. Cephalon, Inc. v. Watson Pharmaceuticals, Inc., 707 F.3d 1330 (Fed. Cir. 2013).

2. Federal Trade Commission. (2015). FTC settlement requires Teva to pay $1.2 billion to resolve charges it violated antitrust laws by delaying generic competition to Provigil.

3. U.S. Food and Drug Administration. (2007). Provigil (modafinil) prescribing information.

4. 21 U.S.C. § 355(j)(5)(B)(iii).

5. U.S. Patent and Trademark Office. (n.d.). Patent Center records for U.S. Patent Nos. 5,618,845, 6,894,051, 7,297,346 and 7,348,363.

6. Teva Pharmaceutical Industries Ltd. (2011). Teva completes acquisition of Cephalon.